Medical physics

Global $30+ Billion Radiation Therapy Quality Assurance (QA) Phantoms Market to 2024: Enhanced Patient and Machine Quality Assurance in Radiation Therapy

Retrieved on: 
Friday, October 25, 2019

The global radiation therapy quality assurance phantoms market is expected to grow at a single-digit compound annual growth rate between the years 2018 and 2024, aided by the enhanced machine and patient quality assurance in radiation oncology, increasing the burden of cancer, and use of tissue-equivalent phantoms.

Key Points: 
  • The global radiation therapy quality assurance phantoms market is expected to grow at a single-digit compound annual growth rate between the years 2018 and 2024, aided by the enhanced machine and patient quality assurance in radiation oncology, increasing the burden of cancer, and use of tissue-equivalent phantoms.
  • The global radiation therapy quality assurance phantoms market is expected to be witnessing an impressive growth of 4.59% in the forecast period 2019-2024.
  • What are the major market drivers, challenges, and opportunities in the global radiation therapy quality assurance phantoms market?
  • Which region carries the potential for the significant expansion of key companies for radiation therapy quality assurance phantoms market?

NEW AGE HEALTH SCIENCES LAUNCHES RADIATION PROTECTION AND HEARING HEALTH PRODUCTS IN JAPAN

Retrieved on: 
Friday, October 25, 2019

New Ages Health Sciences Division (a wholly owned subsidiary of New Age ) was established after the Company acquired the Premier Micronutrient Corporation.

Key Points: 
  • New Ages Health Sciences Division (a wholly owned subsidiary of New Age ) was established after the Company acquired the Premier Micronutrient Corporation.
  • The Company has now launched its radiation protection product and hearing health product under its umbrella NHANCED brand in Japan, following the recent test marketing in Korea in the beginning of the third quarter.
  • Gerald M Haase MD, Chief Medical Officer of the New Age Health Sciences Division, stated Ionizing radiation is particularly injurious to human DNA, cells and tissues causing oxidative stress, inflammation and breakage.
  • About New Age Beverages Corporation (NASDAQ: NBEV )
    New Age is a Colorado-based healthy products company dedicated to inspiring and educating consumers to "live healthy."

Global Radiation Therapy Quality Assurance (QA) Phantoms Markets 2019-2024: Focus on Technology, Therapies, Regions, - ResearchAndMarkets.com

Retrieved on: 
Friday, October 25, 2019

Key Questions Answered in this Report:

Key Points: 
  • Key Questions Answered in this Report:
    What is the industry structure of the global radiation therapy quality assurance phantoms market?
  • How many patents are currently active in the global radiation therapy quality assurance phantoms market?
  • What are the major market drivers, challenges, and opportunities in the global radiation therapy quality assurance phantoms market?
  • The radiation therapy quality assurance phantoms market segmentation (based on therapy) is further segmented into photon beam radiation therapy, stereotactic radiation therapy, advanced 3-D conformal radiation therapy, image-guided radiation therapy, volumetric modulated arc therapy, intraoperative radiotherapy, proton beam therapy, neutron beam therapy, and brachytherapy.

Global Optical Coherence Tomography (OCT) Markets, Technologies & Competition, 2018-2019 & 2024

Retrieved on: 
Friday, October 25, 2019

It is anticipated that medical applications other than ophthalmology will have the fastest growth rate beyond 2020.

Key Points: 
  • It is anticipated that medical applications other than ophthalmology will have the fastest growth rate beyond 2020.
  • The market for OCT light sources and photonics components will represent about 20% and 18% of the total OCT systems market respectively in 2024.
  • SD-OCT is the dominant technology displacing the older TD-OCT. SS-OCT is the newest commercially available technology with advantages for deep tissue penetration.
  • Emerging markets in other medical market segments include cardiology and dermatology as well as other areas.

Aspen Laser Receives Award from Global Health & Pharma

Retrieved on: 
Thursday, October 24, 2019

DENVER, Oct. 24, 2019 /PRNewswire/ --Aspen Laser Systems, LLC, an emerging leader in laser therapy, also referred to as Photobiomodulation, announced that it has been recognized with an award by Global Health & Pharma, a leading publication and information sharing platform, dedicated to the healthcare industry.

Key Points: 
  • DENVER, Oct. 24, 2019 /PRNewswire/ --Aspen Laser Systems, LLC, an emerging leader in laser therapy, also referred to as Photobiomodulation, announced that it has been recognized with an award by Global Health & Pharma, a leading publication and information sharing platform, dedicated to the healthcare industry.
  • Aspen Laser was recognized as the "Best Laser Therapy Provider" in the 2019 International Life Sciences Awards category of Global Health & Pharma.
  • "Since our company began, our focus has been on developing leading-edge technology in laser therapy," said Charles Vorwaller, CEO of Aspen Laser.
  • A copy of the award can be found here: https://www.ghp-news.com/2019-aspen-laser-systems-llc
    To learn more about Aspen Laser, its products, or laser therapy, please visit www.aspenlaser.com , or call 877.782.7736.

Varian ProBeam 360 Proton Therapy System Selected by Penn Medicine for Use in Second Treatment Center

Retrieved on: 
Wednesday, October 23, 2019

PALO ALTO, Calif., Oct. 23, 2019 /PRNewswire/ --Varian (NYSE: VAR) today announced it has been selected by Penn Medicine to install a Varian ProBeam 360 proton therapy system in a single-room configuration at Lancaster General Health Ann B. Barshinger Cancer Institute in south central Pennsylvania.

Key Points: 
  • PALO ALTO, Calif., Oct. 23, 2019 /PRNewswire/ --Varian (NYSE: VAR) today announced it has been selected by Penn Medicine to install a Varian ProBeam 360 proton therapy system in a single-room configuration at Lancaster General Health Ann B. Barshinger Cancer Institute in south central Pennsylvania.
  • In addition to the equipment, Varian will also provide its ARIA information management system and Eclipse treatment planning system.
  • In addition to the agreement on the proton therapy system, Penn Medicine and Varian also signed a research collaboration agreement.
  • "We look forward to continuing our strong partnership with Penn Medicine on the installation of the ProBeam 360 system and increasing access to this advanced technology," said Kolleen Kennedy, chief growth officer and president of Proton Therapy Solutions, Varian.

Global Radiation Therapy Quality Assurance (QA) Phantoms Market: Focus on Technology, Therapies, Regions, Data - Analysis and Forecast, 2019-2024

Retrieved on: 
Wednesday, October 23, 2019

How many patents are currently active in the global radiation therapy quality assurance phantoms market?

Key Points: 
  • How many patents are currently active in the global radiation therapy quality assurance phantoms market?
  • What are the major market drivers, challenges, and opportunities in the global radiation therapy quality assurance phantoms market?
  • Global Radiation Therapy Quality Assurance Phantoms Market Forecast, 2019-2024
    Radiation Therapy Quality Assurance Phantoms Industry Analysis projects the market to grow at a significant CAGR of 4.59% during the forecast period 2019-2024.
  • The radiation therapy quality assurance phantoms market segmentation (based on therapy) is further segmented into photon beam radiation therapy, stereotactic radiation therapy, advanced 3-D conformal radiation therapy, image guided radiation therapy, volumetric modulated arc therapy, intraoperative radiotherapy, proton beam therapy, neutron beam therapy, and brachytherapy.

Intensity Therapeutics’ Intratumoral INT230-6 Tumor Regression and Immune Response Activity Data Selected for Oral Presentation at SITC 2019 Conference

Retrieved on: 
Tuesday, October 22, 2019

Details of the oral presentation are as follows:

Key Points: 
  • Details of the oral presentation are as follows:
    Presenter: Jacob Thomas, MD, Assistant Professor of Clinical Medicine, University of Southern California
    To view the schedule for SITC 2019, please visit: https://www.sitcancer.org/2019/program/annual-meeting-schedule-2019-old .
  • INT230-6 is being evaluated in a Phase 1/2 clinical study ( NCT03058289 ) in patients with various advanced solid tumors.
  • Intensity Therapeutics, Inc. is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers.
  • Intensitys product candidates have the potential to induce an adaptive immune response that not only attacks the injected tumor, but also non-injected tumors and unseen micro-metastases.

Global Optical Coherence Tomography (OCT) Market Forecast Report 2019-2024 | Market is Projected to Exceed $1.2 Billion in 2024 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 21, 2019

It is anticipated that medical applications other than ophthalmology will have the fastest growth rate beyond 2020.

Key Points: 
  • It is anticipated that medical applications other than ophthalmology will have the fastest growth rate beyond 2020.
  • The market for OCT light sources and photonics components will represent about 20% and 18% of the total OCT systems market respectively in 2024.
  • SD-OCT is the dominant technology displacing the older TD-OCT. SS-OCT is the newest commercially available technology with advantages for deep tissue penetration.
  • Emerging markets in other medical market segments include cardiology and dermatology as well as other areas.

Global Optical Coherence Tomography (OCT) Market Outlook to 2024 - SD-OCT is the Dominant Technology Displacing the Older TD-OCT

Retrieved on: 
Monday, October 21, 2019

It is anticipated that medical applications other than ophthalmology will have the fastest growth rate beyond 2020.

Key Points: 
  • It is anticipated that medical applications other than ophthalmology will have the fastest growth rate beyond 2020.
  • The market for OCT light sources and photonics components will represent about 20% and 18% of the total OCT systems market respectively in 2024.
  • SD-OCT is the dominant technology displacing the older TD-OCT. SS-OCT is the newest commercially available technology with advantages for deep tissue penetration.
  • Emerging markets in other medical market segments include cardiology and dermatology as well as other areas.